Experience with Thallium-201 Imaging in Head and Neck Cancer

Ah, Elgazzar; Sahweil, A; Hm, Abdel-Dayem; Kubasik, H; Halker, Rashmi B.; Im, Hassan; Rageb, A; Sm, Abdul-Rahim; Mahmoud, Abdel-Rahman

doi:10.1097/00003072-198804000-00014

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is not specific enough to be useful, however. Uptake of ' 19 "'Tc-HMPAO by gliomas and meningiomas range widely with no significant difference between primary malignant gliomas (0.75 ± 0.27), recurrent malignant gliomas (0.81 ± 0.25), and benign gliomas (0.77 ± 0.21 ). Meningiomas have increased 99111 Tc-HMPAO uptake ( 1.14 ± 0.31) as well.…”

Section: Mtc-hmpao Spectmentioning

confidence: 95%

The Clinical Role of SPECT in Patients with Brain Tumors

Abdel‐Dayem

1995

Journal of Neuroimaging

View full text Add to dashboard Cite

The introduction of computed tomography (CT) in the early 1970s effectively replaced radionuclide brain imaging as the main modality to evaluate the structure and morphology of brain tumors. There are, nevertheless, a number of management problems in patients with suspected brain tumors that can be addressed only by functional imaging. There is the need to determine whether a focal mass detected on CT or magnetic resonance imaging (MRI) is benign or malignant. Since the prognosis of the patient is related to the tumor grade, and because stereotactic biopsy recovers only a small fragment of the tumor, there is the need for an imaging technique that reflects the behavior and the malignancy of the tumor. After treatment, it is important to continue to determine the cause of clinical deterioration in patients with glioma who have received high doses of radiation. Progressive radiation necrosis may require surgical debulking. Detection and localization of solid tumor recurrence, on the other hand, may aid in designing treatment. Positron emission tomography (PET) using 1xF‐fluorodeoxyglucose (18FDG) has been the standard functional imaging modality in these patients. With the introduction of single‐photon emitting brain perfusion tracers in the last decade, brain single‐photon emission computed tomography (SPECT) has reemerged as a useful measure of brain function. Other tracers such as thallium‐201 (201TI) chloride have emerged as tumor markers and have also found a role in brain SPECT. This review evaluates the clinical value and potential of201TI and perfusion brain SPECT in patients with brain tumors

show abstract

Section: Mtc-hmpao Spectmentioning

confidence: 95%

The Clinical Role of SPECT in Patients with Brain Tumors

Abdel‐Dayem

1995

Journal of Neuroimaging

View full text Add to dashboard Cite

show abstract

“…112 Limited experiences with 201 T1 in differentiating recurrence from radiation necrosis in head and neck cancer and in the detection of systemic spread of AIDS-related Kaposi sarcoma --as well as in breast and lung cancer staging --will require further study. [113][114][115]…”

Section: Physiologic Radionuclide Imagingmentioning

confidence: 99%

Newer Imaging Modalities

Berman

Brodsky

1998

Cancer Control

View full text Add to dashboard Cite

This regular feature will enhance your knowledge of imaging technology in oncologic diagnosis, treatment, and evaluation. Tissue-Specific and Physiologic Nuclear Medicine Modalities The search for greater sensitivity for detecting small subclinical tumor deposits and improved specificity for distinguishing between malignant and benign masses has led to the development of techniques for linking radioactive labels to tumor-specific antibodies or tissue-specific biochemical agents. 1,2 Major progress is occurring as well in the development of nonspecific physiologic nuclear medicine modalities, most prominent among them being positron emission tomography (PET) and the recently adapted cardiac imaging agents. The current status of these new approaches is discussed below. Tumor-Specific Monoclonal Antibody Radioimmunoscintigraphy The early use of polyclonal murine antitumor antibodies for tumor localization has been succeeded by monoclonal antibody-based agents, although these, too, are of murine origin thus far. 3,4 The majority of agents under development are labeled with either a technetium 99m (99m Tc) or indium 111 (111 In) radiometal chelate. 5 These are popular because of their ease of preparation, their suitability for standard camera imaging, and the compatibility of their half-lives to the in vivo clearance of the antibody proteins. Whole antibodies and large fragments require the longer half-life of 111 In although this carries with it the disadvantage of high liver clearance, compromising imaging within and adjacent to the liver and, to a lesser extent, the gut. Smaller, more quickly cleared antibody Fab' fragments can be labeled advantageously with the shorter half-lived 99m Tc. Technetium is predominantly cleared by the kidneys, and the combination of fast biologic clearance of the antibody fragment and fast renal clearance of the radiolabel should result in less extensive background activity. Despite their theoretical appeal, the performance of these preparations can still be compromised by problems of poor tumor perfusion, low tumor cell-surface antigen representation, antigen heterogeneity, and nonspecific uptake. 5,6 One approach to reducing the confounding effects of high background activity has been the use of background subtraction techniques, as in the use of 99m Tc-labeled albumin in conjunction with 99m Tc-labeled antibody fragments; however, it is not clear whether improved specificity is in fact achieved. 7 A more recent elaboration on this approach has been the fusion of bone scan or computed tomography (CT) images with single-photon emission tomography (SPECT) images of the radioantibody scan. 8 Only limited experience with these approaches is yet reported. 9 An alternative approach attempts to apply the phenomenon of tumor antigen augmentation from exposure to cytokines such as interferon. 10,11 Here, too, the limited published clinical experience is inadequate to predict whether this phenomenon will be the basis of improved imaging performance. 12 A particularly intriguing approach, champ...

show abstract

Thallium-201 single photon emission computed tomography as an indicator of prognosis for patients with lung carcinoma

Takekawa

Takaoka

Tsukamoto

et al. 1997

Cancer

View full text Add to dashboard Cite

The authors calculated the uptake ratio to evaluate the degree of Tl-201 uptake in the primary tumor. This ratio was compared with survival time and other prognos-1 Department of Respiratory Medicine, Nikko tic factors. Memorial Hospital, Muroran, Japan. RESULTS.The authors studied 152 patients (125 men and 27 women). The group 2 Department of Nuclear Medicine, School of of patients with the low Tl-201 uptake ratio survived longer than the group of Medicine, Hokkaido University, Sapporo, Japan.patients with the high Tl-201 uptake ratio (median survival, 58 weeks vs. 33 weeks; P Å 0.0138 by the log rank test). The multivariate analysis confirmed that the Tl-3 Department of Medical Information Services, Nikko Memorial Hospital, Muroran, Japan.201 uptake ratio was an independent prognostic factor for survival. CONCLUSIONS. These results suggest that the Tl-201 uptake ratio provides indepen-4 First Department of Medicine, School of Medident and objective prognostic information for patients with lung carcinoma. Cancine, Hokkaido University, Sapporo, Japan.

show abstract

Experience with Thallium-201 Imaging in Head and Neck Cancer

Cited by 9 publications

References 0 publications

The Clinical Role of SPECT in Patients with Brain Tumors

The Clinical Role of SPECT in Patients with Brain Tumors

Newer Imaging Modalities

Thallium-201 single photon emission computed tomography as an indicator of prognosis for patients with lung carcinoma

Contact Info

Product

Resources

About